Robert Hershberg
Chief Executive Officer presso HILLEVAX, INC.
Patrimonio netto: 20 M $ in data 31/03/2024
Profilo
Robert M.
Hershberg was the founder of VentiRx Pharmaceuticals, Inc. founded in 2006, where he held the position of President, Chief Executive Officer & Director from 2012 to 2017.
Currently, he holds multiple positions including Chairman, President & Chief Executive Officer at HilleVax, Inc. since 2020, Independent Director at Recursion Pharmaceuticals, Inc. since 2020, Independent Director at Fate Therapeutics, Inc. since 2020, and Independent Director at Adaptive Biotechnologies Corp.
since 2013.
He is also a Director at Cajal Neuroscience, Inc. and a Member at UW Medicine.
He was also a Director at Guide Therapeutics, Inc. and held the position of Assistant Professor at Harvard Medical School.
Dr. Hershberg has a doctorate degree from The Salk Institute for Biological Studies and undergraduate and doctorate degrees from the University of California, Los Angeles.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
HILLEVAX, INC
2.27% | 08/02/2024 | 1 128 033 ( 2.27% ) | 19 M $ | 31/03/2024 |
| 16/06/2023 | 38 619 ( 0.02% ) | 385 031 $ | 31/03/2024 | |
| 04/03/2024 | 107 296 ( 0.07% ) | 344 420 $ | 31/03/2024 | |
FATE THERAPEUTICS, INC.
0.01% | 06/06/2023 | 10 659 ( 0.01% ) | 78 237 $ | 31/03/2024 |
Posizioni attive di Robert Hershberg
| Società | Posizione | Inizio |
|---|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director/Board Member | 01/02/2013 |
| RECURSION PHARMACEUTICALS, INC. | Director/Board Member | 20/03/2020 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 01/05/2020 |
| HILLEVAX, INC. | Chief Executive Officer | 01/03/2020 |
| UW Medicine | Corporate Officer/Principal | - |
Cajal Neuroscience, Inc.
 Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Director/Board Member | - |
Precedenti posizioni note di Robert Hershberg
| Società | Posizione | Fine |
|---|---|---|
| NANOSTRING TECHNOLOGIES, INC. | Director/Board Member | 18/04/2022 |
| CELGENE | Chief Tech/Sci/R&D Officer | 01/01/2019 |
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Chief Executive Officer | 01/03/2017 |
| ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Robert Hershberg
| The Salk Institute for Biological Studies | Doctorate Degree |
| University of California, Los Angeles | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| RECURSION PHARMACEUTICALS, INC. | Health Technology |
| NANOSTRING TECHNOLOGIES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| Aziende private | 8 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Guide Therapeutics, Inc.
 Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Health Technology |
Cajal Neuroscience, Inc.
Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Health Technology |
| HilleVax, Inc. |
- Borsa valori
- Insiders
- Robert Hershberg
